» Articles » PMID: 33296161

Amide-Linked C4″-Saccharide Modification of KRN7000 Provides Potent Stimulation of Human Invariant NKT Cells and Anti-Tumor Immunity in a Humanized Mouse Model

Abstract

Activation of invariant natural killer T (iNKT) cells by α-galactosylceramides (α-GalCers) stimulates strong immune responses and potent anti-tumor immunity. Numerous modifications of the glycolipid structure have been assessed to derive activating ligands for these T cells with altered and potentially advantageous properties in the induction of immune responses. Here, we synthesized variants of the prototypical α-GalCer, KRN7000, with amide-linked phenyl alkane substitutions on the C4″-position of the galactose ring. We show that these variants have weak iNKT cell stimulating activity in mouse models but substantially greater activity for human iNKT cells. The most active of the C4″-amides in our study showed strong anti-tumor effects in a partially humanized mouse model for iNKT cell responses. analysis suggested that the tether length and degree of flexibility of the amide substituent affected the recognition by iNKT cell antigen receptors of the C4″-amide substituted glycolipids in complex with their antigen presenting molecule CD1d. Our findings establish the use of stable C4″-amide linked additions to the sugar moiety for further exploration of the immunological effects of structural modifications of iNKT cell activating glycolipids and highlight the critical need for more accurate animal models to assess these compounds for immunotherapeutic potential in humans.

Citing Articles

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy.

Palacios P, Flores I, Cereceda L, Otero F, Muller M, Brebi P Cancers (Basel). 2025; 17(3).

PMID: 39941775 PMC: 11815936. DOI: 10.3390/cancers17030406.


Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.

Gutierrez-Vera C, Garcia-Betancourt R, Palacios P, Muller M, Montero D, Verdugo C Front Immunol. 2024; 15:1364774.

PMID: 38629075 PMC: 11018981. DOI: 10.3389/fimmu.2024.1364774.


A Humanized Mouse Model Coupled with Computational Analysis Identifies Potent Glycolipid Agonist of Invariant NKT Cells.

Saavedra-Avila N, Pigni N, Caldwell D, Chena-Becerra F, Intano Jr J, Ng T ACS Chem Biol. 2024; 19(4):926-937.

PMID: 38477945 PMC: 11075374. DOI: 10.1021/acschembio.3c00736.


Natural Killer T Cell Diversity and Immunotherapy.

Tognarelli E, Gutierrez-Vera C, Palacios P, Pasten-Ferrada I, Aguirre-Munoz F, Cornejo D Cancers (Basel). 2023; 15(24).

PMID: 38136283 PMC: 10742272. DOI: 10.3390/cancers15245737.


Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine.

Hu X, Xian M, Wang X, Zou G, Luo R, Peng H ACS Med Chem Lett. 2023; 14(12):1647-1655.

PMID: 38116441 PMC: 10726466. DOI: 10.1021/acsmedchemlett.3c00154.


References
1.
Borg N, Wun K, Kjer-Nielsen L, Wilce M, Pellicci D, Koh R . CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature. 2007; 448(7149):44-9. DOI: 10.1038/nature05907. View

2.
Pauwels N, Aspeslagh S, Elewaut D, Van Calenbergh S . Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands. Bioorg Med Chem. 2012; 20(24):7149-54. DOI: 10.1016/j.bmc.2012.09.063. View

3.
Im J, Arora P, Bricard G, Molano A, Venkataswamy M, Baine I . Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity. 2009; 30(6):888-98. PMC: 2719696. DOI: 10.1016/j.immuni.2009.03.022. View

4.
Arora P, Venkataswamy M, Baena A, Bricard G, Li Q, Veerapen N . A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids. J Am Chem Soc. 2011; 133(14):5198-201. PMC: 3072113. DOI: 10.1021/ja200070u. View

5.
Jervis P, Graham L, Foster E, Cox L, Porcelli S, Besra G . New CD1d agonists: synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides. Bioorg Med Chem Lett. 2012; 22(13):4348-52. PMC: 3401990. DOI: 10.1016/j.bmcl.2012.05.009. View